Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR438544 vs Glucagon in T1DM Hypoglycemia
NCT02635243Phase 1Withdrawn
- Sponsor
- Sanofi
- Start
- Apr 2016
- Primary completion
- Nov 2016
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of SAR438544 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Sanofi. Primary endpoint: Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product at Day 1. Planned start Apr 2016; status: withdrawn.
02
Drugs
SAR438544
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02635243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635243.